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Circulating Biomarkers to Identify 
Responders in Cardiac Cell therapy
Jesse V. Jokerst1, Nicholas Cauwenberghs  2, Tatiana Kuznetsova2, Francois Haddad3, 
Timothy Sweeney  3, Jiayi Hou4, Yael Rosenberg-Hasson3, Eric Zhao1, Robert Schutt5, 
Roberto Bolli6, Jay H. Traverse7, Carl J. Pepine8, Timothy D. Henry9, Ivonne H. Schulman10, 
Lem Moyé11, Doris A. Taylor12 & Phillip C. Yang3
Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) 
has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma 
samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 
61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left 
ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated 
the clinical value of circulating proteins in outcome prediction using significance testing, partial least 
squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had 
higher biomarker levels (76–94% elevated) than non-responders. Several biomarkers had values that 
differed significantly (P < 0.05) between responders and non-responders including stem cell factor, 
platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis 
and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These 
biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive 
power. We conclude that plasma profiling after STEMI may help identify patients with a greater 
likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive 
value of the circulating biomarkers.
Cell-based cardiac therapy has produced encouraging but inconsistent results in treating ischemic heart dis-
ease1–3. One current hypothesis is that its efficacy is limited because of poor engraftment into the heart after 
delivery and rapid cell death2,4. Schemes to increase cell survival and engraftment include, among many other, 
support scaffolds5 and co-delivery of pro-survival agents6,7. However, these approaches do not address a deeper 
issue: within any patient population that there is likely a wide variation in the effectiveness of stem cells. Current 
inclusion criteria for ST-elevation myocardial infarction (STEMI) cell therapy trials8 largely use cardiac function 
indexes such as left ventricular ejection fraction (LVEF). Yet, these indices only reflect the extent of cardiac dam-
age after reperfusion and provide guideline for subsequent medical therapy. They offer no molecular level infor-
mation to better identify patients who would benefit from cell therapy. In addition to current selection criteria, 
circulating proteins might have additional value in predicting individual response to cell therapy. Such biomark-
ers and cytokines might indicate a robust microenvironment capable of promoting cell survival and functional 
recovery. Just as biomarkers for graft-versus-host disease following allogeneic hematopoietic cell transplantation 
have the promise to predict response9,10, we hypothesized that this approach might identify positive responders 
in cell-based therapy for STEMI patients.
Candidate biomarkers include circulating proteins such as stem cell factor (SCF), stromal cell derived factor 
(SDF1), and colony stimulating factors11, which are known to have a role in myocardial regeneration. Similarly, 
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biomarkers involved in cell growth (e.g. vascular endothelial growth factor; VEGF)12, repair (tumor necrosis 
factor α; TNFα)12, adhesion (vascular cell adhesion molecule; VCAM1)13, and inflammation (interleukins and 
chemokines) might predict the outcome of cell therapy.
In this study, we measured 63 circulating proteins in baseline serum samples obtained from reperfused STEMI 
patients (N = 138) who were then treated with autologous BM-MNCs (150 × 106) or placebo. The data were 
obtained from both the TIME14 and LateTIME trials15 conducted by the Cardiovascular Cell Therapy Research 
Network. While these trials did not show an aggregate benefit to therapy relative to placebo controls, there were 
“responders”, i.e., patients in whom cardiac function improved, within both the cell-treated and placebo-treated 
cohorts. Our goal here was to profile the serum of responders and non-responders in both cohorts and identify 
the differences in biomarker profiles, which correlated positively with a response to cell therapy.
To the best of our knowledge, this is the first report to profile a set of circulating biomarkers and investigate 
their clinical value in predicting the response to cardiac cell therapy after STEMI. These biochemical signatures 
may improve the selection of STEMI patients and personalize cell therapy.
Methods
Enrollment and Specimens. Banked plasma samples were obtained from the TIME (clinicaltrials.gov no. 
NCT00684021) and Late-TIME trial (clinicaltrials.gov No. NCT00684060), which were conducted between July 
2008 and November 2011. Both studies assessed left ventricle function at baseline and six months after intracoro-
nary delivery of BM-MNCs after STEMI. BM-MNC administration was performed 3 and 7 days (TIME) or 14–21 
days (Late-TIME) after reperfusion. The primary inclusion criterion was a left ventricle ejection fraction (LVEF) 
<45% as assessed by echocardiography. Specimens in TIME were collected within a week of the myocardial 
infarction. Specimens in LateTIME were in general 2–3 weeks after the infarction. Patients with previous bypass 
surgery or prior STEMI with residual left ventricular dysfunction were excluded. Blood samples were collected 
after reperfusion but prior to administration of cells in tubes containing EDTA as an anticoagulant. Blood sam-
ples were centrifuged and plasma was decanted and stored at −80 °C. All samples were collected after subjects 
provided written informed consent. This study received Institutional Review Board approval by the University 
of Texas IRB. All patients provided written informed consent following broad discussions of the risks, benefits, 
and alternatives of the TIME and LateTIME trials. All methods were performed in accordance with the relevant 
guidelines and regulations and the Declaration of Helsinki.
Data Analysis. Patients were classified as either responders or non-responders based on the original outcome 
data. For example, a patient with a positive ΔEF was considered a responder as was a patient with a decreased 
ΔEDVI. In addition to the five metrics above, we also included a subset of high ΔEF responders. These were 
patients with a ΔEF of >5 (absolute increase in ΔEF >5). Next, for each biomarker, a mean and two-sided stu-
dent’s t-test were calculated using the raw mean fluorescent intensity (MFI) data. This MFI approach has utility 
when samples have low levels of biomarker because interpretation with a sigmoidal calibration curve can suppress 
subtle differences16.
We compared the mean biomarker levels between the cell-treated and placebo-treated cohort, and calculated 
P values (2-tailed, homoscedastic) to determine the significance of these changes. These significant biomarkers 
as well as biomarkers with mean values of more than 2.0-fold different between responders and non-responders 
were characterized with receiver operating characteristic (ROC) curve; an area under the curve (AUC) and an 
associated P value was calculated with GraphPad Prism. P values < 0.05 were considered statistically significant.
Partial Least Square Discriminant Analysis (PLS-DA). PLS-DA analysis used SAS software, ver-
sion 9.3, and JMP Genomics, version 6.0 (SAS Institute, Cary, North Carolina). Samples were adjusted for age, 
sex, and BMI. Using PLS-DA, we assessed the relation between circulating biomarkers and absolute or relative 
changes in ejection fraction (EF), end diastolic volume index (EDVI), end systolic volume index (ESVI), infarct 
zone wall motion (INZ), or border zone wall motion (BDZ) analyzed as continuous variables. In categorical 
analysis, we identified a pattern of cytokines associated with response to stem cell therapy (responders versus 
non-responders). PLS-DA creates several linear combinations (latent factors) of the log-transformed predictors to 
maximize the covariance between the predictors and the outcome variables16,17. We assumed that the number of 
latent factors was not significantly different from the model with the minimum predicted residuals sum of squares 
(PRESS) value18. These latent variables were then used in the discrimination analysis instead of the original indi-
vidual predictors (biomarkers).
The importance of each cytokine in the construction of the latent variables is assessed from the variables 
importance for projection (VIP) scores as proposed by Wold16,19. In both continuous and categorical analy-
sis, cytokines with a VIP >1.5 were considered influential. The distributions of all cytokines were analyzed by 
transformation to the common logarithm. The VIP score was calculated as the sum of the squared correlations 
between the latent factors and the biomarker, weighted for the percentage of variation explained by the latent 
factors in the model. Finally, V-plots were constructed to illustrate the importance of each biomarker in the model 
(VIP, x axis) in relation to the coefficient size of each biomarker (y axis). These V plots illustrate the contribution 
of all biomarkers to the model used to explain outcome as well as their effect on the outcome.
Net Reclassification Index (NRI). We also performed NRI analysis in the cell-treated patients to deter-
mine whether the selected biomarkers better reclassified the treated patients by response. The default classifier 
consisted of age and sex, whereas the new classifier additionally included the latent factor(s) derived from the 
informative biomarkers and related to the treatment response (dEF, dEDV, etc.)
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Results
Clinical Features of the Study Population. Detailed descriptions of the trial participants are availa-
ble in the TIME14 and Late-TIME15 manuscripts. The majority of the participants were male (73%), white 
(78%), and hyperlipidemic (70%). Table 1 lists the clinical and biochemical characteristics of the responders 
(ΔEF > 0, n = 49) and non-responders (ΔEF ≤ 0, n = 29) in the cell treated group. We noted no significant dif-
ference in clinical, demographic and biochemical characteristics between the two subgroups (P ≥ 0.09; Table 1). 
We repeated the comparison between responders who received BM-MNCs and responders who received pla-
cebo. Just as in the BM-MNC group, placebo “responders” has a positive outcome (+ΔEF, −ΔEDVI, −ΔESVI, 
+ΔINZ, or +ΔINZ). These were patients in TIME or LateTIME who received placebo and had a positive out-
come (response). The only significant difference between placebo responders and cell treatment responders was 
in baseline heart rate; (72.4 ± 19.9 in the treated cohort; 81.8 ± 22.2 bpm in the placebo cohort; P = 0.035).
Luminex Assay Quality Control. We validated the assays using standard curves and calibration sam-
ples for every biomarker according to standard Luminex protocols (Fig. 1)16,20,21. The inset and caption of Fig. 1 
lists the complete biomarker cohort and describes their potential role in cardiac repair. The coefficient of varia-
tion (CV) of the assays were below 12% except for IL-22 (55.1%), IL-23 (23.3%), MCP1 (27.7%), and RANTES 
(15.3%). The reason for the large CV values is that these assays had low bead counts (<~25 beads). While these 
results were included in subsequent analysis, only RANTES showed any correlation with outcome or predictive 
power. Thus, the RANTES data should be interpreted with caution.
Baseline Biomarker Levels in Responders versus Non-responders. Next, the mean of the 63 bio-
markers measured in the baseline samples were compared between the responders and non-responders using the 
raw data (MFI). We used these mean values to compare the fold-change in biomarker levels between responders 
and non-responders (Fig. 1) in both the BM-MNC-treated and placebo cohorts.
The fold-change in the ΔEF cohort is measured by averaging the biomarker value of responders normalized to 
the average biomarker value of non-responders in the treated cohort (Fig. 1). Assuming an equal and random dis-
tribution, one would expect approximately the same number above and below a value of unity (red line), but this 
is not the case in the BM-MNC-treated group. The majority (≥76%) of the 63 baseline biomarkers were increased 
in BM-MNC-treated responders versus non-responders regardless of the response metric. For the ΔEF response 
metric, 50 of the 63 biomarkers were elevated (79%) in responders at baseline (Fig. 1), and other outcome metrics 
followed a similar trend: ΔEDVI (59/63 biomarkers or 94%); ΔESVI (48/63, 76%); ΔINZ (52/63, 83%); ΔBDZ 
(48/63, 76%); and ΔEF > 5 (52/63, 83%). In placebo-treated subjects, ≤76% of the biomarkers were elevated in 
responders: ΔEF (48/63; 76%); ΔEDVI (34/63; 54%); ΔESVI (39/63, 62%); ΔINZ (26/63, 41%); ΔBDZ (32/63, 
51%); and ΔEF > 5 (28/63, 44%).
In many of the highest fold-changes (e.g., PDGFBB in Fig. 1), the high fold-change is largely due to only one 
or two outliers. Biomarkers with significant differences between the two patient cohorts as well as significant 
values for both BM-MNC-treated and placebo subjects are presented in Table 2. Although these values did not 
achieve significance when analyzed with a Bonferroni correction, our goal here is to identify new relationships 
that require confirmation rather than generalize our results to the population at large. The biomarker with the 
highest AUC value for each type of outcome metric is reported as well as a representative ROC curve for IL9 
(Fig. 2). Multiple biomarkers had AUC values over 0.60.
Discrimination Analysis using PLS-DA for Identification of Important Biomarkers in Stem Cell 
Response. The V plots (Fig. 3 for continuous, Fig. 4 for categorical) show a cytokine variable importance 
in projection (VIP) score in modeling of latent factors versus the centered and scaled correlation coefficients 
Cell Treated Placebo
Non-Responders Responders P values Non-Responders Responders P 
values(n = 28) (N = 49) (n = 18) (N = 42)
Age (y) 59.8 ± 11.7 56.1 ± 11.4 0.17 54.4 ± 11.2 55.9 ± 11.2 0.64
Gender (male) 23 (79%) 41 (84%) 0.63 14 (78%) 39 (93%) 0.099
BMI 28.8 ± 4.7 28.9 ± 5.8 0.96 30.1 ± 5.8 29.1 ± 4.6 0.48
Hgb (g/dL) 13.8 ± 1.6 13.6 ± 1.3 0.60 12.8 ± 1.6 13.5 ± 1.9 0.21
hsCRP 22.7 ± 36.5 23.6 ± 27.2 0.90 35.1 ± 30.8 27.0 ± 31.5 0.4
CKMB (U/mL) 341 ± 269 271 ± 172 0.24 319 ± 261 250 ± 179 0.29
HR (bpm) 79.9 ± 18.0 72.4 ± 19.9 0.10 87.0 ± 17.4 81.8 ± 22.2 0.38
EF (%) 48.9 ± 11.9 44.3 ± 10.9 0.09 46.0 ± 10.2 43.0 ± 9.4 0.28
Hyperlipidemia 21 (72%) 34 (69%) 0.78 13 (72%) 29 (69%) 0.81
Angina 6 (20%) 12 (24%) 0.70 3 (17%) 6 (14%) 0.82
Diabetes 6 (20%) 5 (10%) 0.20 4 (22%) 8 (19%) 0.78
HTN 17 (59%) 28 (57%) 0.90 11 (61%) 25 (60%) 0.91
Smoking 15 (51%) 32 (65%) 0.24 11 (61%) 26 (62%) 0.95
Table 1. Clinical features of responders (ΔEF > 0) and non-responders (ΔEF > 0) treated with either cell BM-
MNCs or placebo. Values are mean (±SD) or number of subjects (%).
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between cytokine and outcome. Cytokines with higher VIP values (VIP > 1.5) were more important for class 
discrimination. Cytokines with the highest VIP values and positive correlation with respect to the outcome are 
present in the upper far right quadrant while cytokines with the highest VIP values and negative correlation with 
respect to the outcome are placed in the upper far left quadrant.
Biomarkers with elevated VIP values (VIP > 1.5) in continuous and categorical PLS-DA analysis are presented 
in Supplementary Table 1 and Table 2, respectively. Overall, we observed that a higher IL15, IL5, and SCF were 
related to more favorable changes in several LV indexes in the BM-MNC-treated group: increase in ΔEF, ΔINZ 
and ΔBDZ and decrease in ΔEDVI and ΔESVI (Supplementary Table 3; Figs 3 and 4). Moreover, in categorical 
analyses, a higher IL15 was related to a greater increase in ΔEF and ΔBDZ after cell therapy, whereas a higher 
SCF significantly predicted a more favorable response in ΔEF and LV volume indexes (Supplementary Table 1; 
Fig. 3). Furthermore, in both continuous and categorical PLS analyses, MCP1, IL27, and IL12p70 were predictive 
of the decrease in EDVI and ESVI after cell therapy (Supplementary Tables 1 and 2; Figs 3 and 4). We additionally 
defined a subset of patients presenting a trio of favorable responses, i.e. ΔEF > 0, ΔESVI < 0, and ΔEDVI < 0 
(n = 18; Supplementary Table 4, Fig. 4F). In these ‘triple-responders’, biomarkers with positive coefficients and 
high VIP included: VCAM1 (VIP, 1.51), SCF (2.17), PDGFBB (1.53), MCSF (1.78), IL27 (1.80), IL13 (1.63), 
IL12p70 (2.04), and BDNF (1.71).
PLS-DA analysis was repeated in placebo patients (Supplementary Tables 3 and 4) and identified several bio-
markers that were predictive of changes in outcome. These biomarkers correlated to improved outcome inde-
pendent of cell therapy. Importantly, the biomarkers identified in the placebo group did not correspond to those 
in the treatment group (IL15, IL5, SCF, etc.).
Figure 1. Biomarkers used in the study. Fold change of responders (ΔEF > 0) versus non-responders 
(ΔEF ≤ 0) is demonstrated. Dashed inset graph shows the representative calibration curve for stem cell factor. 
Right upper table shows the broad classes of the biomarkers used in present study. Abbreviations. BDNF: 
brain-derived neurotrophic factor; CXCL: chemokine; EGF: epidermal growth factor; ENA78: CXCL5; FASL: 
fatty acid synthase ligand; FGF2: fibroblast growth factor; G-CSF: granulocyte colony-stimulating factor; GM-
CSF; granulocyte macrophage colony-stimulating factor; GROA: CXCL1; HGF: human growth factor; ICAM: 
intercellular adhesion molecule; IL: interleukin; IP10: interferon gamma-induced protein (CXCL10); LIF: 
leukemia inhibitory factor; MCP: monocyte chemoattractant protein; M-CSF: macrophage colony-stimulating 
factor; MIG: CXCL9; MIP: macrophage inflammatory protein; NGF: nerve growth factor; PAI1: plasminogen 
activator inhibitor; PDGF-B: platelet derived growth factor; RANTES: regulated on activation normal T 
cell expressed and secreted (aka CCL5); SCF: stem cell factor; SDF1: stromal cell derived factor; TGFA: 
transforming growth factor α; TNF: tumor necrosis factor; TRAIL: TNF-related apoptosis-inducing ligand; 
VCAM: vascular adhesion molecule; VEGF: vascular endothelial growth factor.
BM-MNC-Treated Subjects Placebo Subjects
ΔEF IL27 (0.05); Eotaxin (0.009); IL1B (0.044)
ΔESVI IL27 (0.049); IL5 (0.042); NGF (0.045); IL15 (0.0040); IL18 (0.048)
ΔEDVI VCAM1 (0.04) None
ΔINZ FASL (0.004); IL4 (0.04); IL8 (0.003); IL31 (0.005); IL9 (0.016); IL1B (0.012)
ΔBDZ Eotaxin (0.021); IL9 (0.048); IL12p40 (0.047) HGF (0.040); VEGFD (0.017)
ΔEF > 5 Eotaxin (0.029); IL1RA (0.042); IL12p40 (0.025) None
Table 2. Biomarkers with a p value <0.05 between responders vs. non-responders for different outcome metrics 
in both BM-MNC-treated and placebo cohorts.
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Finally, we compared the biomarker levels in placebo responders and BM-MNC responders to determine if 
there were any inherent differences in baseline physiology. Here, we only used the LVEF metric. None of the lead 
biomarkers identified above were different between the two sets of responders. Biomarkers that did have a signif-
icant difference included: MCP3, IL18, PAI1, TNFa, IFN-G, RANTES, IL13, and IL6.
Net Reclassification Index (NRI). The NRI is only statistically significant for dEF (Table 3), but the P value 
for NRI is heavily dependent on the number of subjects. As in most NRI analyses, we should not overestimate the 
importance of this NRI P value and instead focus on the absolute NRI. Absolute NRI was high (>0.20) for dEF, 
dINZ, dBDZ and the triple responders, indicating a strong difference in the proportion of patients reclassified by 
Figure 2. (A). Representative ROC for IL9 with the ΔINZ metric gives an AUC of 0.73 (P < 0.001). Biomarkers 
with the highest AUC value for each type of outcome metric are shown in panel B.
Figure 3. V-plots for continuous PLS-DA models generated with extracted VIP and correlation coefficient 
values for the BMC-treated subjects. Biomarkers with high VIP (>1.5) and coefficient values are named. V-plots 
for continuous change in in (A) EF, (B) EDVI, (C) ESVI, and (D) INZ.
www.nature.com/scientificreports/
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the set of biomarkers selected by PLS between the two sets of non-responder & responder. In short, it thus might 
be clinically relevant to assess this set of biomarkers for prediction of response to SC treatment.
Discussion
We identified significant differences in biomarker concentrations between cell therapy responders and 
non-responders that changed as a function of the different outcome metrics. This finding was attributed to the 
multiple metrics, which were used to classify different patient response. One consistent finding, however, was 
the up-regulation of all biomarkers in the responders compared to the non-responders. While increased levels of 
cytokines predict worse outcomes in hematopoietic cell therapy22, the potential clinical role of the baseline measure-
ment of these cytokines in cell therapy for heart disease may enable a personalized approach to predict responders.
Myocardial infarction results in an inflammatory cascade as the body removes dead cells and matrix debris 
from the necrotic region while also activating repair mechanisms. Thus, we suspected that the patients in the 
TIME trial would have higher cytokine levels because they were enrolled at an earlier time point after the onset 
of STEMI. However, of the 63 biomarkers, 36 were higher in the Late-TIME patients and 27 were higher in the 
TIME subjects. Only two—IL1RA and IL12P40—showed a significant difference between the two trials. While 
prolonged periods of inflammation produced worse outcomes and decreased cardiac function23, it is possible 
that elevated levels of cytokines attracted circulating endogenous stem cells, activated endogenous resident stem 
Figure 4. V-plots for categorical PLS-DA models generated with extracted VIP and correlation coefficient 
values for BMC-treated subjects. Biomarkers with high VIP (>1.5) and coefficient values are named. V-plots for 
a favorable change in (A) EF, (B) EDVI, (C) ESVI, (D) INZ, (E) BDZ, and (F) EF, EDVI + ESVI.
Therapy response NRI (95% CI) NRI P value Event P value Non-Event P value
ΔEF > 0% (n = 49) 0.48 (0.05 to 0.90) 0.035 0.32 0.056
ΔEDVI < 0 (n = 33) 0.030 (−0.41 to 0.47) 0.90 0.67 0.60
ΔESVI < 0 (n = 42) 0.19 (−0.24 to 0.63) 0.39 0.89 0.22
ΔINZ > 0 (n = 43) 0.25 (−0.18 to 0.68) 0.26 0.89 0.12
ΔBDZ > 0 (n = 44) 0.35 (−0.08 to 0.79) 0.12 0.32 0.22
Triple response 
(n = 18) 0.33 (−0.04 to 0.70) 0.14 0.032 0.0003
Table 3. Net Reclassification Index (NRI) Analysis for PLS Selected Biomarkers in SC Treated Patients.
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cells24 or initiated self-repair response to complement the cell therapy. Thus, patients with an overall elevated pool 
of these biomarkers (at least during this baseline measurement) might be more receptive to endogenous repair.
Different biomarkers were implicated in different analysis methods and different outcome metrics. The pre-
viously reported factors implicated in cardiac repair, e.g., VEGF, SDF1, and GSCF25,26 did not have a pronounced 
effect in this study. The most frequent biomarkers were SCF and IL15, which were implicated in all analysis meth-
ods. SCF had an AUC of 0.63 (ROC P = 0.049) and IL15 had an AUC of 0.70. VCAM-1 was implicated with simple 
t-testing but ROC analysis did not confirm this finding. Others have suggested that VCAM-1 was a poor predic-
tor of heart disease outcomes27. Eotaxin, an eosinophil chemotactic protein, was implicated in multiple outcome 
metrics28. PDGFBB and MIP1 were implicated in stem cell migration and their elevated levels in the responder 
suggested recruitment of endogenous stem cells29,30. A previous study of MCP1, RANTES, and MIP1a showed that 
the patients with severe left ventricular dysfunction had elevated levels of these markers one month after STEMI31.
The PLS-DA analysis identified candidate biomarkers that were consistently up-regulated in patients who 
responded via multiple outcome metrics. These highly cross-related markers included SCF, MCSF, and IL12p70, 
which could have roles in either priming the stem cell niche or supporting the implanted stem cells. MCSF and 
IL12p70 are implicated in the activation of monocytes and T-cells, respectively, and thus may have a role in 
immune clearance of necrotic tissue; SCF supports stem cell recruitment and activation. SCF, the ligand for c-Kit, 
was reported to activate multiple signaling pathways including RAS/ERK, PI3-Kinase, Src kinase, and Janus 
kinase/signal transducer, the activator of JAK/STAT transcription pathways32.The JAK/STAT pathway can mobi-
lize mesenchymal stem cells and may help maintain cardiac function33 after cell therapy in this subset of patients. 
In one study, overexpression of SCF by cardiomyocytes was shown to promote stem cell migration and improve 
outcome after MI34, and thus patients with elevated levels of SCF might be more receptive to cell therapy.
IL-15 was highly implicated with multiple outcome metrics. It has been reported to activate natural killer (T) cell 
proliferation and hematopoiesis35,36. Rodent studies showed an anti-apoptotic role for IL-15 with anti-tumor activ-
ity37. Elevated IL-15 might protect stem cells and encourage proliferation. A recent study of showed that IL-15 and 
MCP-1 indicate myocardial response to ischemic insult in the early phase after MI via an inflammatory response38. 
Other cytokines like IL-8 and ENA78 correlated with improved outcomes (Figs 3 and 4). These chemokines contain 
the ELR motif (such as IL-8) and can induce neutrophil infiltration to exert angiogenic effects39.
One limitation of this study is its retrospective design. It was impossible to do biomarker profiling before 
therapy due to the retrospective study design, however we compared all treated subjects and placebo subjects 
(ignoring responders versus responders) to see if there were any differences in biomarkers levels. The follow-
ing biomarkers had a significant (p < 0.05, simple t-test) difference: TNFA, IFNG, PAI1, IL18, IFNA, IL6, NGF, 
MCP3, RANTES, EOTAXIN, IL17A, IL4, IL10, IL22, GMCSF, BDNF, IL12P40, IL1RA, GCSF, and MCSF. 
However, none of these biomarkers were implicated as predictive in our PLS-DA analysis. Importantly, there was 
no statistically significant difference in the placebo and treatment cohort for IL-15, SCF, or PDGFBB, which were 
the most predictive biomarkers.
Future prospective studies are needed to confirm the panel of biomarkers identified in our study as predictors 
of cell therapy response in the early phase following STEMI. However, the use of both placebo and cell-treated 
subjects was an important step to validate the findings. The leads generated in the cell-treated cohort were not 
implicated in the placebo-treated group. Other targets for future panels include osteopontin40,41, exosomes, con-
nexin 4342, and novel small molecules including miRNA.
We observed that the patients who improved after placebo also had biomarkers that correlated with outcome. 
Some of these biomarkers were also seen in the BM-MNC-treated cohort including Eotaxin and MIP1a, which 
suggests that these improvements might occur regardless of cell therapy. However, IL-15 and SCF were the two 
lead candidates from the BM-MNC-treated group that had no correlation in the placebo subjects. Thus, elevated 
levels of these markers may have a specific role in increasing the efficacy of autologous BM-MNC therapy.
Baseline biomarker measurement is a relatively quick and affordable approach to personalized management 
of patients, which could increase the efficacy of cell therapy via more rational and precise inclusion criteria. This 
study demonstrated specific cytokines in both BM-MNC and control groups, which led to improved cardiac func-
tion measure. The limitations of this study include the relatively low number of subjects leading to small sample 
bias. Clearly, our findings require confirmation in replication cohorts with larger patient populations. Another 
limitation is that the TIME and Late-TIME studies did not show aggregate improvements in the cell-treated 
patients relative to the placebo-treated patients.
Conclusion
In this study, we identified a set of circulating plasma proteins associated with a favorable response to BM-MNC 
therapy after STEMI. The identified biomarkers might improve the selection criteria to conduct precision med-
icine, which personalizes the therapeutic decision and enhances the clinical outcome of STEMI patients under-
going stem cell treatment.
Data Availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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